June 02, 2022
1 min watch
Nemeroff CB, et al. Neurobiology and remedy of post-traumatic stress dysfunction. Offered at: American Psychiatric Affiliation annual assembly; Could 21-25, 2022; New Orleans.
Disclosures: Nemeroff stories receiving analysis grants from NIH; consulting for AbbVie, Acadia Prescribed drugs, Alfasigma, ANeuroTech (division of Anima BV), BioXcel Therapeutics, Clexio, Corcept Therapeutics Prescribed drugs Co., EcoR1, EMA Wellness, Engrail Therapeutics, GoodCap Prescribed drugs, Intra-Mobile Therapies, Magstim, Navitor Prescribed drugs, Pasithea Therapeutic Corp., Sage, Senseye, Signant Well being, Silo Pharma, SK Life Science and XW Pharma; in addition to being a stockholder for Antares, BI Gen Holdings, Corcept Therapeutics Prescribed drugs Co., EMA Wellness, Naki Well being, Seattle Genetics, TRUUST Neuroimaging and Xhale.
NEW ORLEANS – Plenty of new remedies are on the horizon for PTSD, making the longer term shiny for sufferers with this situation, Charles B. Nemeroff, MD, PhD, mentioned on the American Psychiatric Affiliation annual assembly.
Ketamine, sure psychedelics and the usage of neuromodulation resembling transcranial magnetic stimulation are new choices, Nemeroff, of the College of Texas at Austin Dell Medical Faculty, mentioned.